Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial-Reference-Cited by-同舟云学术

Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

Published:2018-05-30 Issue:1 Volume:38 Page:31
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Qin Yan¹,Song Yuqin²,Shen Zhixiang³,Du Xin⁴,Ji Wei⁵,Hsu Wanling⁶,Zhu Jun²,Shi Yuankai¹

Affiliation:

1. Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing 100021 P. R. China

2. Department of Lymphoma, Beijing Cancer Hospital; Peking University; Beijing 100142 P. R. China

3. Department of Hematology, Ruijin Hospital; Shanghai Jiaotong University; Shanghai 200025 P. R. China

4. Department of Hematology; Guangdong General Hospital/Guangdong Academy of Medical Sciences; Guangzhou 510030 Guangdong P. R. China

5. Clinical Science; Shanghai Roche Pharmaceuticals Ltd; Shanghai 201203 P. R. China

6. Statistics; Roche (China) Holding Ltd; Shanghai 201203 P. R. China

Funder

F. Hoffmann-La Roche Ltd.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-018-0300-5.pdf

Reference23 articles.

1. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008;Mak;Leuk Lymphoma,2014

2. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases;Li;J Diagn Concepts Pract,2012

3. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma;Cheson;N Engl J Med.,2008

4. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998

5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol.,1998

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

2. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment;Frontiers in Immunology;2023-12-01

3. CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia;Experimental Hematology & Oncology;2023-01-12

4. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma;Chinese Medical Journal;2021-09-16

5. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29